Relmada Therapeutics, Inc.
DE ˙ DB ˙ US75955J4022
5,30 € ↓ -0,05 (-0,93%)
2026-06-04
AKTIENPREIS
SecurityDE:4E2 / Relmada Therapeutics, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership126,672 shares
Latest Disclosed Value $ 881,637
UBS Group AG reports 205.47% increase in ownership of 4E2 / Relmada Therapeutics, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 126,672 shares of Relmada Therapeutics, Inc. (DE:4E2) valued at $696,696 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 41,468 shares of Relmada Therapeutics, Inc.. This represents a change in shares of 205.47% during the quarter. The current value of the position is $671,362 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F RELMADA THERAPEUTICS COM 75955J402 126,672 85,204 205.47 882 340.50 0.0000
2026-01-29 2025-12-31 13F RELMADA THERAPEUTICS COM 75955J402 41,468 -18,317 -30.64 200 66.67 0.0000
2025-11-13 2025-09-30 13F RELMADA THERAPEUTICS COM 75955J402 59,785 -120,686 -66.87 120 11.11 0.0000
2025-08-14 2025-06-30 13F RELMADA THERAPEUTICS COM 75955J402 180,471 35,682 24.64 108 176.92 0.0000
2025-05-13 2025-03-31 13F RELMADA THERAPEUTICS COM 75955J402 144,789 -70,351 -32.70 39 -64.86 0.0000
2025-02-14 2024-12-31 13F RELMADA THERAPEUTICS COM 75955J402 215,140 88,755 70.23 112 -72.86 0.0000
2024-11-14 2024-09-30 13F RELMADA THERAPEUTICS COM 75955J402 126,385 -2,415 -1.88 409 5.96 0.0001
2024-08-14 2024-06-30 13F RELMADA THERAPEUTICS COM 75955J402 128,800 -485 -0.38 386 -35.77 0.0001
2024-05-13 2024-03-31 13F RELMADA THERAPEUTICS COM 75955J402 129,285 3,555 2.83 601 15.58 0.0001
2024-02-09 2023-12-31 13F RELMADA THERAPEUTICS COM 75955J402 125,730 42 0.03 521 37.93 0.0002
2023-11-09 2023-09-30 13F RELMADA THERAPEUTICS COM 75955J402 125,688 26,700 26.97 377 55.14 0.0001
2023-08-11 2023-06-30 13F RELMADA THERAPEUTICS COM 75955J402 98,988 97,410 6,173.00 244 8,000.00 0.0001
2023-05-12 2023-03-31 13F RELMADA THERAPEUTICS COM 75955J402 1,578 -4,335 -73.31 4 -85.00 0.0000
2023-02-08 2022-12-31 13F RELMADA THERAPEUTICS COM 75955J402 5,913 -171 -2.81 21 -91.11 0.0000
2022-11-10 2022-09-30 13F RELMADA THERAPEUTICS COM 75955J402 6,084 4,756 358.13 225 800.00 0.0001
2022-08-10 2022-06-30 13F RELMADA THERAPEUTICS COM 75955J402 1,328 0 0.00 25 -30.56 0.0000
2022-05-16 2022-03-31 13F RELMADA THERAPEUTICS COM 75955J402 1,328 -1,869 -58.46 36 -50.00 0.0000
2022-02-14 2021-12-31 13F RELMADA THERAPEUTICS COM 75955J402 3,197 -1,522 -32.25 72 -41.94 0.0000
2021-11-15 2021-09-30 13F RELMADA THERAPEUTICS COM 75955J402 4,719 98 2.12 124 -16.22 0.0000
2021-08-13 2021-06-30 13F RELMADA THERAPEUTICS COM 75955J402 4,621 -1,925 -29.41 148 -35.65 0.0000
2021-05-12 2021-03-31 13F RELMADA THERAPEUTICS COM 75955J402 6,546 -873 -11.77 230 -3.36 0.0001
2021-02-11 2020-12-31 13F RELMADA THERAPEUTICS COM 75955J402 7,419 1,805 32.15 238 12.80 0.0001
2020-11-12 2020-09-30 13F RELMADA THERAPEUTICS COM 75955J402 5,614 -2,747 -32.85 211 -43.58 0.0001
2020-07-31 2020-06-30 13F RELMADA THERAPEUTICS COM 75955J402 8,361 5,318 174.76 374 259.62 0.0002
2020-05-01 2020-03-31 13F RELMADA THERAPEUTICS COM 75955J402 3,043 -1,214 -28.52 104 -37.35 0.0000
2020-02-14 2019-12-31 13F RELMADA THERAPEUTICS COM 75955J402 4,257 4,257 166 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.